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Here we report a unique method of ribosomally synthesizing fused tricyclic peptides. Flexizyme-assisted
in vitro translation of a linear peptide with the N-terminal chloroacetyl group and four downstream cys-
teines followed by the addition of 1,3,5-tris(bromomethyl)benzene results in selective production of the
fused tricyclic peptide. This technology can be used for the ribosomal synthesis of fused tricyclic peptide
libraries for the in vitro selection of bioactive peptides with tricyclic topology.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Some naturally occurring peptides consist of complex macro-
cyclic structures [1]. For instance, conotoxins, cyclotides and
defensins possess multicyclic frameworks and exhibit remarkable
thermostability, serum stability and in some cases oral bioavail-
ability [2–4]. Such peptides are also composed of unique structural
elements such as head-to-tail cyclization, cysteine (Cys) knot
motifs and multiple intramolecular disulﬁde bonds. These struc-
tural elements are thought to be what give rise to their various bio-
logical activities. Hence, these frameworks have gained interest
and have been investigated for use as scaffolds for drug discovery
[5].
Several methods involving the chemical macrocyclization of
peptides to mimic the beneﬁts seen in naturally occurring peptides
have been reported [6–10]. One reliable method is to take advan-
tage of the selective reactivity of Cys residues with appropriate
chemical reagents, such as benzyl halides [6,8–11]. Heinis et al.
have used such macrocyclization methods with phage display to
select for bicyclic peptides using libraries of peptides which con-
tain three Cys residues that are bicyclized by the post-translation
addition of 1,3,5-tris(bromomethyl)benzene (TBMB) [9]. This
method was able to select for a bicyclic peptide with a remarkable
IC50 of 1.5 nM against human plasma kallikrein. Macrocyclic
peptides inhibiting thrombin via mRNA displayed libraries con-
taining N- and C-terminal Cys residues and monocyclized using
a,a-dibromoxylene have been also reported [10].Cyclization strategies using genetic code reprogramming have
also made it possible to generate macrocyclic peptide libraries
with diversities up to the trillions [12]. These methods have been
coupled with in vitro display technologies to rapidly select for cyc-
lic peptides with exceptional bioactivity [13–18]. A very robust
method of generating macrocyclic peptides by means of genetic
code reprogramming via the FIT (Flexizyme-assisted in vitro trans-
lation) system [19,20] is to aminoacylate the initiator tRNAfMetCAU
with an amino acid containing an N-chloroacetyl (ClAc) group.
The N-terminal ClAc group is able to form a sulﬁde bond with
the sidechain sulfhydryl group of a downstream Cys resulting in
thioether macrocyclic peptides [19]. When a single Cys exists in
a downstream position, the selective intramolecular formation of
the thioether bond occurs to yield a monocyclic structure. When
more than one Cys exists on the peptide, the foremost
N-terminal Cys selectively cyclizes with the N-terminal ClAc group
[21]. However, cyclization between the ClAc group and an adjacent
Cys at the second amino acid position cannot occur due,
most-likely, to steric hindrance or prohibited ring-constrain. This
speciﬁcity has been applied to forming fused bicyclic peptides by
forming a thioether macrocycle between the N-terminal ClAc
group and a second Cys and a disulﬁde bond macrocycle between
a Cys in the second amino acid position and a third Cys [21].
To generate peptides with a more complex cyclic scaffold, we
here report a method that enables us to ribosomally synthesize
fused tricyclic peptides via in vitro translation systems. Taking
advantage of the aforementioned cyclization selectivity, we envi-
sioned that by translating peptides with the N-terminal ClAc
group, one Cys residue at the second position and three more arbi-
trarily spaced downstream Cys residues, followed by the addition
Fig. 1. Schematic representation for the ribosomal production of tricyclic peptides. (a) The Cys in the second amino acid position is not able to react with the N-terminal
chloroacetyl group therefore the next closest Cys reacts to form a thioether bond. (b) Addition of TBMB to the monocyclic peptide forms thioethers with the remaining three
Cys residues resulting in a peptide with a fused tricyclic topology.
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cyclic peptides of various sizes and amino acid compositions
(Fig. 1).
2. Materials and methods
2.1. Oligonucleotides and DNA templates
DNA oligonucleotides were purchased from Euroﬁns Genomics
and are listed in Table 1. DNA templates used for the translation of
peptides in this study were produced via assembly PCR by mixing
an FW oligonucleotide with an RV primer with a corresponding
name. These products were ampliﬁed by using T7gAUG as a for-
ward primer and DGGRK as a reverse primer except in the case
of 3C10 where 3C10RV2 was used as a reverse primer.
2.2. Methionine(-) Flexizyme assisted In vitro Translation (FIT) system
All in vitro translations in this study were performed using a
methionine-deﬁcient version of the FIT system [20]. The composi-
tion of the FIT system, sans pre-aminoacylated tRNAs, are as fol-
lows: 1.2 lM ribosome, T7 RNA polymerase, 4 lg/mL creatine
kinase, 3 lg/mL myokinase, 0.1 lM pyrophosphatase, 0.1 lM
nucleotide-diphosphatase kinase, 0.73 lM AlaRS, 0.02 lM CysRS,Table 1
Sequences of oligonucleotides used in this study.
Name Peptide Oligonucleotide Sequences (50 to 30)
L7FW P1 TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATAT
L7RV TTTCCGCCCCCCGTCTTATTTCGCATCACACGGGATGCGCAG
L7eFW P1e TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATAT
L7eRV TTTCCGCCCCCCGTCTTATTTCGCATCACACGGGATGCGCAG
3C1FW P2 TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATAT
3C1RV TTTCCGCCCCCCGTCTTACGAACCTTTGCCGCTGCGATAATC
3C5FW P3 TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATAT
3C5RV TTTCCGCCCCCCGTCTTACGAACCTTTGCCGCTGCGATAATC
3C10FW
P4
TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATAT
3C10RV GGCTTGCGCAACGCTTCACGGCCGCAGTTACGGTGCTGTAC
3C10RV2 TTTCCGCCCCCCGTCTTAGCGACCTTTACACTCCGAAGGCTT
3C5AFW P5 TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATAT
3C5ARV TTTCCGCCCCCCGTCTTAGGAGCCTTTGCCGCTACGGAAGT
3C5BFW P6/P6F TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATAT
3C5BRV TTTCCGCCCCCCGTCTTACGACCCTTTACCCGAGCGCTTGTC
3C5CFW P7 TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATAT
3C5CRV TTTCCGCCCCCCGTCTTAAGAACCTTTACCAGAACGTTTATC
T7gAUG N/A TAATACGACTCACTATAGGGTTAACTTTAAGAAGGAGATAT
DGGRK N/A TTTCCGCCCCCCGTCTTA0.13 lM, AspRS, 0.23 lM GluRS, 0.68 lM PheRS, 0.09 lM GlyRS,
0.02 lM HisRS, 0.4 lM IleRS, 0.11 lM LysRS, 0.04 lM
LeuRS, 0.03 lM MetRS, 0.38 lM AsnRS, 0.16 lM ProRS, 0.06 lM
GlnRS, 0.03 lM ArgRS, 0.04 lM SerRS, 0.09 lM ThrRS,
0.02 lM ValRS, 0.03 lM TrpRS, 0.02 lM TyrRS, 0.26 lM EF-G,
10 lM EF-Tu, 10 lM EF-Ts, 2.7 lM IF1, 0.4 lM IF2, 1.5 lM IF3,
0.6 lM MTF, 0.25 lM RF2, 0.17 lM RF3, 0.5 lM RRF, 0.1 lM,
1.5 mg/mL Escherichia coli total tRNA, 0.5 mM of all 20 proteino-
genic amino acids except for methionine, 2 mM ATP, 1 mM UTP,
2 mM GTP, 1 mM CTP, 2 mM spermidine, 20 mM creatine
phosphate, 2 mM DTT, 50 mM HEPES–KOH (pH 7.6), 12 mM mag-
nesium acetate, 100 mM potassium acetate.
2.3. Aminoacylation of tRNAs via ﬂexizymes
tRNAs, ﬂexizymes and activated amino acids were synthesized
as previously described [20]. tRNAfMetCAU was aminoacylated
with cyanomethyl ester activated N-chloroacetyl D-tryptophan
(ClAc-DW) or N-chloroacetyl L-tyrosine (ClAc-LF). tRNAfMetCAU and
eFx were mixed to a ﬁnal concentration of 25 lM with a MgCl2
concentration of 600 mM in 50 mM HEPES–KOH pH 7.5. To this,
the aforementioned cyanomethyl ester activated amino acid was
added to a ﬁnal concentration of 5 mM. After a 1 h incubation on
ice, the reaction contents were precipitated using an 70% ethanol,ACATATGTGTGGCACCATCGCAAGCAAACACTGCGGCTCCGCCCTTGTG
AGCTTCACCACAGTGCTGCACAAGGGCGGAGCCGCAG
ACATATGTGTGGCACCATCGCAAGCAAACACTGCGGCTCCATGCTTGTGCAGCAC
AGCTTCACCACAGTGCTGCACAAGCATGGAGCCGCAG
ACATATGTGCGGCTGCGGTTGCGGCTGC
GCAGCCGCAACCGCAGCC
ACATATGTGCGGCACCATTGCGAGCTGCGGTTCGTTTAGCCTGTGCGGCCGTGAAGCG
GCACAGCGCTTCACGGCCGCACAGG
ACATATGTGCGGCACCATTGCGAAATTGCACGGTGCGATCTGCGGG
CAAGGAACCTTTCCCGCAGATCGCACCGTGC
GCGCAACGCTTCACG
ACATATGTGTGGAACGAATGCAAGTTGCGGTAGTTACAGCTTATGTGGG
CACACAGCGCTTTGCGCCCACATAAGCTGTAACTACCGCAACTTGC
ACATATGTGTGGTACTGATCAAGCCTGCGGGAGTTGGTCTTTATGTGG
GCAGAGGGCTTCGCGTCCACATAAAGACCAACTCCCGCAGGC
ACATATGTGCGGAACCATCGCCTCTTGCGGTAGCCACAGTCTCTGTGGC
ACAAAGAACAGGGCGGCCACAGAGACTGTGGCTACCGCAAG
ACATATG
Fig. 2. Peptide tricyclization and MALDI-TOF MS/MS fragmentation analysis. (a) The DNA template D1 was expressed to produce peptide P1. P1 is predicted to spontaneously
monocyclize to form mP1 and reaction with 1,3,5-tris(bromomethyl)benzene (TBMB) results in the tricyclic peptide tP1. (b) MALDI-TOF MS analysis of mP1 (mP1
mobs = 3094.45 Da mcalc = 3094.45) and tP1 (tP1 mobs = 3208.50 Da mcalc = 3208.50). (c) MALDI-TOF MS/MS fragmentation of mP1 (Pm: parent ion) and tP1 (Pt: parent ion).
Due to the high intensity of ions b1 and c1, expanded spectra are shown below. Several peaks corresponding to fragments of mP1 were observed whereas only noise was
observable in the expanded tP1 spectra. (d) Observed fragmentation patterns of mP1 and tP1. Although the fragmentations of mP1 were observed in the linear peptide region,
those of tP1 could not be detected due to the tricyclic topology.
N.K. Bashiruddin et al. / Bioorganic Chemistry 61 (2015) 45–50 470.1 M sodium acetate at pH 5.2. Pellets were kept dry and at 80 C
until use. tRNAenAsnCAU was aminoacylated with L-lactic-acid dini-
trobenzyl ester using dFx by mixing both at a ﬁnal concentration
of 25 lM with a MgCl2 concentration of 600 mM in HEPES-KOH
pH 7.5. To this, L-lactic acid dinitrobenzyl ester was added to a con-
centration of 5 mM and incubated on ice for 3 h followed by
ethanol/sodium acetate precipitation.2.4. Ribosomal synthesis of tricyclic peptides
A methionine deﬁcient FIT system supplemented with a
preaminoacylated ClAc-DW-tRNAfMetCAU was used to in vitro tran-
scribe and translate a DNA template encoding a peptide with
ClAc-DW at the ﬁrst amino acid position a Cys in the second amino
acid positions and three more arbitrarily spaced downstream Cys
residues. Following a 5 ll in vitro translation reaction, 1 ll of
H2O, 1 ll 150 mM TCEP in 0.6 M HEPES KOH pH 7.5 and 1 ll
40 mM TBMB in DMF is added and incubated at 25 C for 1 h. For
MALDI-TOF MS analysis, 12 ll of HBS was added to each sample
and desalted on a C-Tip column (AMR Inc.) and eluted
with a 50% saturated a-cyano-4-hydroxycinnamic acid (Bruker
Daltonics) solution of 80% acetonitrile 0.5% sodium acetate.2.5. Translation, MALDI-TOF MS/MS fragmentation and alkaline
hydrolysis of mP1e peptides
D1e DNA template was used to synthesize mP1e for alkaline
hydrolysis experiments using the Met-deﬁcient FIT system as
described in the previous report [21].2.6. Translation and LC–ESI–MS of peptide P6F
The DNA template for P6 was in vitro translated as in 2.4 at
22 ll scale using a preaminoacylated ClAc-LF-tRNAfMetCAU. The
translation was split into two 10 ll aliquots and tricyclized as in
2.4 or left in monocyclic form by adding only DMF (negative
control). 45 ll of 50% acetonitrile, 0.1% formic acid aq. was added
to each reaction for LC–ESI–MS analysis on a Thermo Accela liquid
chromatograph interfaced to a Thermo Exactive Orbitrap mass
spectrometer. LC was performed on a Phenomenex Aeris Peptide
column (XB-C18, 150 mm  2.1 mm, dp = 3.6 lm) using a 25 min
gradient from 100% solvent A (5% acetonitrile, 10 mM ammonium
formate, 10 mM formic acid aq.) to 100% solvent B (95%
acetonitrile, 10 mM ammonium formate, 10 mM formic acid aq.)
at a 700 ll/min ﬂow rate.
Fig. 3. Determination of monocyclization selectivity in a peptide containing four Cys residues. (a) The mode of initial cyclization of a peptide containing an ester bond
between Cys2 and Cys3 will effect the fragmentation pattern upon alkaline hydrolysis. Cyclization with Cys2 will result in two fragments upon alkaline hydrolysis while
cyclization with Cys3 or Cys4 will result in the opening of the cycle and the addition of H2O. (b) MALDI-TOF analysis of peptide mP1e. The black spectrum shows the peak
corresponding to the full length unhydrolyzed peptide 1 (mobs = 3095.46 Da mcalc = 3095.43). The red spectrum shows peaks corresponding to the N-terminal (1N
mobs = 1289.60 Damcalc = 1289.54) and C-terminal (1C mobs = 1825.01 Damcalc = 1824.91) fragments of mP1e when the ClAc groups reacts with Cys2. A peak corresponding to
remaining unhydrolyzed mP1e 1 (mobs = 3095.62 Damcalc = 3095.43) was observed but no peak corresponding to a hydrolyzed mP1e resulting from cyclization between Cys3
or Cys4 (mcalc = 3113.45 Da) was observed.
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Reassignment of the initiation codon (AUG) with ClAc-DW was
facilitated by the use of a Met-deﬁcient FIT system in the presence
of ClAc-DW-tRNAfMetCAU prepared by the ﬂexizyme, eFx [19]. In
vitro transcription/translation of a DNA template (D1) encoding a
linear 29-mer peptide (P1) successfully expressed the monocyclic
peptide (mP1) via thioether macrocyclization between
the N-terminal ClAc group and a downstream Cys most likely at
position 10 (Fig. 2a and b). mP1 was then treated with
tris(2-carboxyethyl)phosphine (TCEP) followed by addition of
TBMB in DMF. The MALDI-TOF MS analysis of the resulting product
revealed a new peak with a mass shift of 114 Da from that of P1.
This mass difference corresponded to the addition of a mesitylene
moiety to the remaining three Cys residues resulting in a tricyclic
peptide tP1 (Fig. 2a and b).
We have previously demonstrated that the MALDI-TOF MS/MS
fragmentations of macrocyclic peptides allows us to identify the
macrocyclic region over the linear region due to less susceptibility
of the macrocyclic region to fragmentation [22]. Therefore we per-
formed MALDI-TOF MS/MS analysis of tP1 in comparison to mP1.As expected, the linear tail region of mP1 was fragmented to yield
peaks corresponding to the expected residual fragments (Fig. 2c).
On the other hand, tP1 remained intact as one molecule under
the same fragmentation conditions (Fig. 2d). The results suggested
that mP1 was most likely converted to the desired tricyclic
structure of tP1.
Based on our previous experimental data for the ribosomal syn-
thesis of bicyclic peptides [23], we were fairly conﬁdent that the
ﬁrst thioether-macrocyclization took place between the
N-terminal ClAc and the Cys2 residue at position 10, but we felt
that it would be necessary to obtain further evidence to conﬁrm
the fused tricyclic topology. The incorporation of an L-lactic acid
(HOA) at a designated position can be achieved by genetic code
reprogramming. Since we utilized the Met-deﬁcient FIT system
for the reassignment of ClAc-DW, the elongator AUG codon is left
vacant; therefore, this vacant codon can be utilized for the assign-
ment for HOA, similar to the strategy reported elsewhere [18,24].
We thus designed a DNA template (D1e) based on the sequence
of D1 to include an elongator AUG codon between Cys2 and
Cys3, which would be suppressed with HOA by the use of
HOA-tRNAenAsnCAU. When HOA was incorporated into this position
Fig. 4. Ribosomal synthesis of tricyclic peptides with various cycle sizes and amino acid composition. (a) A schematic representation of the topology and the constituents of
ribosomally synthesized tricyclic peptides. (b) MALDI-TOF analysis of peptide P2, P3 and P4 which contain 1, 5 and 10 amino acids between each Cys, respectively (amino acid
sequences are shown above each spectra). Peaks 2, 4 and 6 in the black spectra correspond to monocyclized peptides. Peaks 3, 5 and 7 in the red spectra correspond tricyclic
peptides resulting from the reaction of TBMB with 2, 4 and 6, respectively. The molecular weights of the observed peaks are as follows: 2,mobs = 1678.55 Da (mcalc = 1678.59);
3, mobs = 1792.61 Da (mcalc = 1792.64); 4, mobs = 2954.32 Da (mcalc = 2954.27); 5, mobs = 3068.41 Da (mcalc = 3068.32); 6, mobs = 4162.74 Da (mcalc = 4160.11); 7,
mobs = 4277.26 Da (mcalc = 4274.16). Tricyclization of P2, P3 and P4 gave a MW increase corresponding to the addition of a mesitylene moiety (mcalc = 114.05 Da; 2? 3
mobs = 114.06; 4? 5 mobs = 114.09; 6? 7 mobs = 114.52) (c) MALDI-TOF analysis of P5, P6 and P7 which all together comprise all proteinogenic amino acids expect for
methionine which must be removed to incorporated ClAc-DW. The peaks in the black spectra (8, 10 and 12) correspond to monocyclic peptides and peaks in the red spectra (9,
11 and 13) represent corresponding tricyclic peptides. The molecular weights of the observed peaks are as follows: 8, mobs = 2954.28 Da (mcalc = 2954.28); 9,
mobs = 3068.44 Da (mcalc = 3068.33); 10, mobs = 3001.32 Da (mcalc = 3001.28); 11, mobs = 3115.40 Da (mcalc = 3115.33); 12, mobs = 2905.40 Da (mcalc = 2905.34); 13,
mobs = 3019.48 Da (mcalc = 3019.38). Tricyclization of each peptide gave a MW increase corresponding to the addition of a mesitylene moiety (mcalc = 114.05 Da; 8? 9
mobs = 114.16; 10? 11 mobs = 114.08; 12? 13 mobs = 114.08).
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be selectively cleaved by alkaline hydrolysis, allowing us to verify
the cyclic topology (Fig. 3a). The D1e template was expressed in
the presence of both ClAc-DW-tRNAfMetCAU and HOA-tRNAenAsnCAU.
To facilitate the hydrolysis of the ester bond, we chose position
13 for HOA incorporation neighboring a serine residue at position
12. If macrocyclization occurs as predicted between the
N-terminal ClAc group and the sulfhydryl group on Cys2, we pre-
dicted that alkaline hydrolysis of the ester bond at position 13
would give two peptide fragments detectable by MALDI-TOF MS.
On the other hand, macrocyclization between the ClAc group and
the sulfhydryl group on Cys3 or Cys4 will not result in the forma-
tion of two fragments by the ester hydrolysis.
Ribosomal synthesis of mP1e showed the expected full-length
peak upon MALDI-TOF MS analysis (Fig 3b). Upon alkaline hydrol-
ysis of mP1e, we detected two peaks (one with a mass shift of18 Da corresponding to the addition of H2O) corresponding to the
fragments upstream and downstream of the ester bond, in addition
to a minor peak representing unhydrolyzed product. Notably, no
peak representing a hydrolyzed full-length peptide with a 18 Da
mass shift from the addition of H2O was observed, indicating that
selective cyclization occurred between the N-terminal ClAc group
and Cys2, and not between the N-terminus and Cys3 or Cys4.
Thus, we concluded that the ﬁrst thioether-macrocyclization
occurred between the N-terminus and Cys2, and the following
TBMB-mediated cyclization occurred between the sulfhydryl
groups on Cys1, Cys3, and Cys4, to yield the tricyclic peptide with
the topology as predicted.
We ﬁnally examined to see whether the same method could be
applied to peptides composed of various lengths between Cys2,
Cys3, and Cys4. We designed three DNA templates encoding
peptides P2, P3 and P4 composed of 1, 5 and 10 amino acids between
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showed a 114 Da increase compared to theirmonocyclized counter-
parts onMALDI-TOFMSanalysis.Moreover,wedesignedanother set
of three DNA templates varying in amino acid composition based on
the framework of P3 (P5, P6 and P7). Indeed,wewere able to detect a
peakwith a 114 Da increase from themonocyclic peptide, indicating
the formation of tricyclic peptides. These results conﬁrmed that the
tricyclization method was applicable to various peptides regardless
of length and amino acid composition. Further, to test for any possi-
ble side reactions, LC–ESI–MS (Liquid Chromatography–ElectroSpr
ay Ionization–Mass Spectrometry) analysis was performed using
the template for P6 with ClAc-LF as the initiator amino acid (P6F)
andonlynegligibleamountsof side reactionproductswereobserved
(Fig. S1, see more details in the supplementary discussion). This
analysis indicates that the tricyclization method reported here
allows us to cleanly convert the linear peptide expressed in the FIT
system to the topologically controlled tricyclic peptide via
spontaneous thioether-macrocyclization between the N-terminal
ClAc and Cys2 followed by TBMB-mediated Cys1–Cys3–Cys4
thioether-crosslinking.
4. Conclusion
To summarize, we have demonstrated a unique method of con-
verting ribosomally synthesized thioether monocyclic peptides
into fused thioether tricyclic peptides by the addition of TBMB.
This method is compatible with peptides of various lengths and
amino acid compositions, and therefore it can be readily adapted
to the ribosomal synthesis of DNA-encoded tricyclic peptide
libraries. Moreover, because of the methodological simplicity and
clean conversion from linearly expressed peptides to complex
fused tricyclic peptides, the method can be coupled with in vitro
display platforms, such as the RaPID (Random non-standard
Peptides Integrated Discovery) system. Upon constructing such a
platform, we will be able to perform selection of bioactive species
that tightly bind to drug targets and readily deconvolute their
novel peptide sequences.
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